Form 4: Centessa Pharmaceuticals Director Brett I.W. Zbar Acquires Share Options

Director Brett I.W. Zbar of Centessa Pharmaceuticals plc reports the acquisition of share options, though disclaims beneficial ownership except for pecuniary interest.

Summary

• Brett I.W. Zbar, a director of Centessa Pharmaceuticals plc, filed a Form 4 on June 27, 2024, reporting a transaction.
• On June 25, 2024, Zbar acquired share options for 48,000 ordinary shares at an exercise price of $8.89.
• The share options vest on the earlier of the first anniversary of the grant date or the Issuer's next annual meeting of shareholders, contingent upon continued service as a director.
• Zbar disclaims beneficial ownership of these share options and the underlying ordinary shares, except to the extent of any pecuniary interest, as the options are held for the benefit of General Atlantic Service Company, L.P.

Sentiment

Score: 5

Explanation: The document is a standard regulatory filing regarding share option grants, indicating a neutral sentiment.

Industry Context

This filing is a routine disclosure related to insider transactions, specifically the granting of share options to a director. It's a common practice for companies to incentivize and retain directors through equity-based compensation.

Stakeholder Impact

• The granting of share options could potentially align the director's interests with those of the shareholders, incentivizing value creation.

Key Dates